Pharma
Johnson & Johnson to buy Proteologix for $850m
J&J will acquire drugs in development for eczema and asthma.
Stay updated on Clinical Development trends and industry impact. Healthcare Brew provides the latest news and professional analysis on Clinical Development's role in Drug Discovery & Development and Pharma.
J&J will acquire drugs in development for eczema and asthma.
The British drugmaker saw a steep decline in sales of its Covid-19 vaccine and antibody drugs in 2023.
CEO Pascal Soriot expects a “very substantial decline” in 2023 Covid-related sales.
Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed.
By subscribing, you accept our Terms & Privacy Policy.